Meritage Portfolio Management Has $1.74 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Meritage Portfolio Management raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 8.8% in the 4th quarter, HoldingsChannel reports. The firm owned 48,181 shares of the specialty pharmaceutical company’s stock after buying an additional 3,886 shares during the period. Meritage Portfolio Management’s holdings in Supernus Pharmaceuticals were worth $1,742,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SUPN. GAMMA Investing LLC raised its position in shares of Supernus Pharmaceuticals by 97.1% in the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 398 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Supernus Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after acquiring an additional 352 shares during the period. KBC Group NV lifted its position in Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after acquiring an additional 929 shares during the last quarter. Kennebec Savings Bank bought a new stake in shares of Supernus Pharmaceuticals during the third quarter worth approximately $103,000. Finally, Janney Montgomery Scott LLC acquired a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $211,000.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 9.30% of the stock is owned by insiders.

Supernus Pharmaceuticals Trading Down 1.3 %

Shares of SUPN stock opened at $39.48 on Thursday. The stock has a market cap of $2.18 billion, a P/E ratio of 36.90 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28. The stock has a 50 day simple moving average of $37.29 and a 200 day simple moving average of $34.69.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The firm had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. During the same period in the prior year, the company posted ($0.29) EPS. The company’s revenue was up 14.2% compared to the same quarter last year. Analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current year.

Wall Street Analyst Weigh In

SUPN has been the subject of several recent research reports. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals in a research note on Monday, January 6th. They issued an “overweight” rating and a $57.00 price target on the stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.